Programmed death ligand 1 testing: is there one best test?
作者信息
Hirsch Fred R
机构信息
University of Colorado Denver School of Medicine, Denver, Colorado.
出版信息
Clin Adv Hematol Oncol. 2017 Jun;15(6):438-440.
PMID:28749902
Abstract
摘要
相似文献
1
Programmed death ligand 1 testing: is there one best test?程序性死亡配体1检测：是否存在一种最佳检测方法？
Clin Adv Hematol Oncol. 2017 Jun;15(6):438-440.
2
Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?非小细胞肺癌患者程序性死亡配体1检测：准备好进入黄金时期了吗？
Cancer Cytopathol. 2017 Aug;125(8):591-593. doi: 10.1002/cncy.21882. Epub 2017 Jun 16.
3
Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.程序性死亡配体1免疫组化检测在非小细胞肺癌实际诊疗中的应用
Cancer Cytopathol. 2017 Jul;125(7):521-528. doi: 10.1002/cncy.21873. Epub 2017 May 4.
4
[The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].[程序性死亡受体-1/配体抗体治疗非小细胞肺癌的预测生物标志物]
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Oct 12;41(10):799-803. doi: 10.3760/cma.j.issn.1001-0939.2018.10.010.
5
[Quiz: Ready, study, score!].[小测验：准备、学习、得分！]
Ann Pathol. 2017 Feb;37(1):7-10. doi: 10.1016/j.annpat.2016.12.014. Epub 2017 Feb 1.
6
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.程序性细胞死亡蛋白1配体1异质性在非小细胞肺癌患者接受免疫治疗选择中的意义
Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.
7
PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?程序性死亡配体-1（PD-L1）表达作为一种预测性生物标志物：没有证据是否等同于证据不存在？
JAMA Oncol. 2016 Jan;2(1):54-5. doi: 10.1001/jamaoncol.2015.3782.
8
Programmed cell death ligand 1 as a biomarker in head and neck cancer.程序性细胞死亡配体1作为头颈癌的生物标志物
Cancer Cytopathol. 2017 Jul;125(7):529-533. doi: 10.1002/cncy.21872. Epub 2017 May 4.
9
Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.支气管内超声引导下经支气管针吸活检术评估非小细胞肺癌程序性死亡配体-1表达的临床性能
Diagn Cytopathol. 2018 May;46(5):378-383. doi: 10.1002/dc.23900. Epub 2018 Feb 24.
10
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.PD-L1检测在选择非小细胞肺癌患者进行PD1/PD-L1导向治疗中的临床应用。
Clin Pharmacol Ther. 2016 Sep;100(3):212-4. doi: 10.1002/cpt.385. Epub 2016 Jun 3.
Zotero 插件